Management of Locally Advanced and Metastatic Esophageal Cancer in the Older Population-Reference-Cited by-同舟云学术

Management of Locally Advanced and Metastatic Esophageal Cancer in the Older Population

Published:2018-11-13 Issue:12 Volume:20 Page:
ISSN:1523-3790
Container-title:Current Oncology Reports
language:en
Short-container-title:Curr Oncol Rep

Author:

Bracken-Clarke Dara,Farooq Abdul Rehman,Horgan Anne M.

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/article/10.1007/s11912-018-0745-3/fulltext.html

Reference89 articles.

1. SEER Cancer Statistics Review, 1975-2015 [Internet]. Surveillance Research Program of the NCI. 2018. Available from: https://seer.cancer.gov/csr/1975_2015/ .

2. • van Putten M, de Vos-Geelen J, Nieuwenhuijzen GAP, Siersema PD, Lemmens V, Rosman C, et al. Long-term survival improvement in oesophageal cancer in the Netherlands. Eur J Cancer. 2018;94:138–47 This article reports the trends in diagnosis, treatment, histology and survival for oesophageal cancer in the Netherlands Cancer Registry in the period 1989–2014. It reports incidence, subtype, survival, age and treatment modality—thus yielding extensive demographic and therapeutic data across time.

3. •• van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84 This article reports the Dutch CROSS trial, assessing the efficacy of neoadjuvant chemoradiotherapy (carboplatin/paclitaxel, 41.4Gy) followed by surgery vs surgery alone for locally advanced oesophageal cancer. Although fewer older patients were included, it represents a worldwide standard-of-care for trimodality therapy in oesophageal cancer. Thus, it remains highly relevant in any treatment plan for locally advanced disease.

4. • Stahl M, Budach W. Definitive chemoradiotherapy. J Thorac Dis. 2017;9(Suppl 8):S792–S8 This review discusses the various regimens (both chemotherapy and radiotherapy) used for radical treatment of oesophageal cancer. There is less focus on age however side effect data and long-term remission rate with chemoradiotherapy +/- surgery—which may be a very important factor in the older population.

5. Shao MS, Wong AT, Schwartz D, Weiner JP, Schreiber D. Definitive or preoperative chemoradiation therapy for esophageal cancer: patterns of care and survival outcomes. Ann Thorac Surg. 2016;101(6):2148–54.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Individualized treatment decision model for inoperable elderly esophageal squamous cell carcinoma based on multi-modal data fusion;BMC Medical Informatics and Decision Making;2023-10-23

2. Geriatric Radiation Oncology: What We Know and What Can We Do Better?;Clinical Interventions in Aging;2023-05

3. Concomitant preoperative airflow obstruction confers worse prognosis after trans-thoracic surgery for esophageal cancer;Frontiers in Surgery;2023-01-16

4. Best Supportive Care of the Patient with Oesophageal Cancer;Cancers;2022-12-19

5. Management of elderly patients with esophageal squamous cell cancer;Japanese Journal of Clinical Oncology;2022-04-30